Login to Your Account



Amgen-Novartis migraine drugs sails toward filing

By Michael Fitzhugh
Staff Writer

Thursday, November 17, 2016

A high dose of the late-stage migraine prevention therapy erenumab (AMG 334), co-developed by Amgen Inc. and Novartis AG, trimmed about two more migraine days than placebo from an average 8.3 monthly migraine days experienced by patients during the last three months of a confirmatory phase III trial. A low dose of the antibody bested placebo by a lesser 1.4 days. Safety was comparable to placebo, Amgen said.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription